Search Results for: arbiter

Final results of ARBITER 6-HALTS confirm CIMT benefit with niacin and no benefit with ezetimibe

Last November the initial presentation at the AHA and simultaneous publication in the New England Journal of Medicine of the ARBITER 6-HALTS trial resulted in a storm of confusion and controversy. Now the final results of the trial have been published in the Journal of the American College of Cardiology. The data appear to provide…

Click here to continue reading…

Report: New niacin scrips rise 41% in week following ARBITER 6

Following the release of ARBITER 6 last Sunday, new prescriptions for Niaspan (extended-release niacin, Abbott) rose 41% over the week before, according to SDI, a market research firm that tracks prescriptions….

Click here to continue reading…

One week later: the ARBITER 6 aftermath

One week after the slightly premature release of ARBITER 6, the most important clinical trial in the history of medicine a small surrogate endpoint trial, the medical experts, Wall Street analysts, and the media have declared that nothing really changed because of the trial….

Click here to continue reading…

Sunday at the AHA: ARBITER’s wild roller coaster ride in Orlando

[Updated. See bottom of story for postscript on CNBC TV reporter Mike Huckman’s embargo break.] The early release of the ARBITER 6 trial on Sunday was a roller coaster ride in more ways than one. In addition to the drama in the newsroom at the AHA as the embargo was lifted, the hastily assembled news…

Click here to continue reading…

AHA: Niacin to take center stage as it beats ezetimibe in ARBITER 6

Following a frenzied build-up (on Wall Street, at least– not so much in the medical community) the results of ARBITER 6 have now been presented at the AHA and published online in the New England Journal of Medicine. The bottom line: niacin but not ezetimibe caused a significant reduction in CIMT. Although its HDL raising…

Click here to continue reading…

The empire strikes back: Merck’s Richard Pasternak downgrades ARBITER 6

In response to the growing frenzy on Wall Street and in the media over the upcoming presentation of ARBITER 6 on Monday morning, Merck’s Richard Pasternak (formerly a cardiologist at Massachusetts General Hospital) sent a lengthy critique of the trial to CardioBrief (see below). Pasternak also wrote a detailed response to an article about ARBITER 6…

Click here to continue reading…

Editorial: Why ARBITER 6 is important– and not important

Arbiter-6 is big news. CNBC will be reporting live from the convention hall on Monday when the results are released. Just in the last day or so the New York Times and the Wall Street Journal have discussed the significance– or lack of it– of the trial. On the one hand, most cardiologists I speak…

Click here to continue reading…

ARBITER-6 Family Feud: And the survey says…

If cardiology and medicine were as simple as Family Feud then ARBITER-6 would already be decided. (For those of you not familiar with it, Family Feud, as described by Wikipedia, is a TV game show “that pits two families against each other in a contest to name the most popular responses to a survey-type question posed…

Click here to continue reading…

Small niacin imaging study looms large in the run-up to ARBITER-6

In the context of growing anticipation and speculation about ARBITER-6, observers in the medical community and on Wall Street are taking a close look at a small JACC study evaluating  the impact of niacin on carotid atherosclerosis as assessed by MRI….

Click here to continue reading…

ARBITER-6: Wall Street chorus predicts outcome, publication, and editorials (updated)

November 2 Update: CardioBrief has learned from a reliable source that ARBITER-6 and accompanying editorials will in fact be published in the New England Journal of Medicine. October 29: Wall Street analysts, in a growing chorus, are confidently predicting that niacin will enjoy a decisive victory over ezetimibe in ARBITER 6, the much discussed trial…

Click here to continue reading…

ARBITER-6 scheduled as AHA Late-Breaker, Kastelein to be discussant

ARBITER-6 is scheduled to be presented as a late-breaking clinical trial on Monday, November 16 at 11:07 AM. The discussant for the trial will be John Kastelein. Several knowledgeable observers have pointed out that, as the principal investigator of the highly controversial ENHANCE trial, and as a lecturer and consultant for numerous companies, including Merck…

Click here to continue reading…

Wall Street guesses ARBITER-6 will be AHA late-breaker

Updated (story originally published on August 17)– Wall Street analysts are speculating that ARBITER 6 will be presented as a late-breaker at this year’s AHA meeting in Orlando in November. Wells Fargo analyst Larry Biegelsen last week wrote that “we expect the ARBITER 6 HALTS study to be presented as a late-breaker at the AHA in…

Click here to continue reading…

ARBITER 6-HALTS trial comparing ezetimibe and niacin terminated early by steering committee

============================================== Click here to see all of CardioBrief‘s coverage of ARBITER-6 ============================================== Updated with clarifications from Allen Taylor, Abbott, and Schering-Plough– ARBITER 6-HALTS, a trial comparing ezetimibe to extended-release niacin in 400 patients already taking statins, has been terminated early by an independent steering committee. According to a statement entered on June 16, 2009 on…

Click here to continue reading…

LDL-Lowering Genetic Variants Linked to Diabetes Risk

–What can genetics tell us about diabetes incidence with cholesterol drugs? Editor’s note: The following guest post was contributed by Marilyn Mann, a well-known advocate for patients with familial hypercholesterolemia and a patient advisor to Circulation: Cardiovascular Quality and Outcomes. In a study published in the Journal of the American Medical Association, several LDL-lowering genetic…

Click here to continue reading…

FDA Rejects Proposed Chronic Kidney Disease Indication for Vytorin

The FDA rejected a new indication for Merck’s Vytorin and Zetia (ezetimibe plus simvastatin and ezetimibe alone) in chronic kidney disease patients. As a consolation prize, however, the agency approved a new label for Vytorin that will incorporate the results of SHARP (Study of Heart and Renal Protection), which found that Vytorin reduced the incidence of…

Click here to continue reading…

NHLBI Stops the AIM-HIGH Trial of Niacin

(Updated with comments from William Boden, Sanjay Kaul, James Stein, Monty Krieger, and Allen Taylor)– The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health) trial of niacin has been stopped early by the NHLBI. The trial was designed to test the addition of high dose, extended-release niacin (Niaspan) to statins…

Click here to continue reading…

CardioExchange at the AHA: A New Voice Emerges

Some of you may be aware that my “day job” for the last year has been with the Massachusetts Medical Society, publishers of NEJM. I’ve been working with the great people at MMS helping develop and publish CardioExchange, a social media website for cardiovascular healthcare professionals. Now that may sound silly to many of you…

Click here to continue reading…

Avandia: a plaque on both your houses!

Comment on the News: Avandia continues to dominate cardiovascular-related news this week. Last night the AHA and the ACC issued a highly detailed, thoughtful, though perhaps slightly over-diplomatic science advisory on TZDs and CV risk. Taking a completely opposite tack, GSK, in no mood to take prisoners, and apparently about to nominate itself for a…

Click here to continue reading…